Nuclear receptors in cell life and death

Trends in Endocrinology and Metabolism

Volumn 12, Issue 10, 2001, Pages 460-468

  Altucci, Lucia ^a   Gronemeyer, Hinrich ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; LIGAND;

ANIMAL; APOPTOSIS; CELL COMPARTMENTALIZATION; CELL CYCLE; CELL SURVIVAL; DRUG DESIGN; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; REVIEW;

ANIMALS; APOPTOSIS; CELL COMPARTMENTATION; CELL CYCLE; CELL SURVIVAL; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0035651027     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00502-1     Document Type: Review

References (116)

1. Silberstein, G.B. et al. (1994) Essential role of endogenous estrogen in directly stimulating mammary growth demonstrated by implants containing pure antiestrogens. Endocrinology 134, 84-90
2. Couse, J.F. and Korach, K.S. (1999) Estrogen receptor-null mice: what have we learned and where will they lead us? Endocr. Rev. 20, 358-417
3. Lydon, J.P. et al. (1996) Reproductive phenotypes of the progesterone receptor null mutant mouse. J. Steroid Biochem. Mol. Biol. 56, 67-77
4. Yee, D. and Lee, A.V. (2000) Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia 5, 107-115
5. Russo, I.H. and Russo, J. (1998) Role of hormones in mammary cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 3, 49-61
6. Clemons, M. and Goss, P. (2001) Estrogen and the risk of breast cancer. New Engl. J. Med. 344, 276-285
7. Lupulescu, A. (1995) Estrogen use and cancer incidence: a review. Cancer Invest. 13, 287-295
8. Tonetti, D.A. and Jordan, V.C. (1999) The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. J. Mammary Gland Biol. Neoplasia 4, 401-413
9. Fabian, C.J. (2001) Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res. 3, 99-103
10. O'Regan, R.M. and Jordan, V.C. (2001) Chemoprevention of breast cancer. Cancer Treat. Res. 106, 137-154
11. Rhodes, D.J. et al. (2000) Breast cancer prevention trials. Curr. Oncol. Rep. 2, 558-565
12. De Sombre, E.R. and Jensen, E.V. (2000) Steroid hormone binding and hormone receptors. In Cancer Medicine (Holland, J.F et al., eds), pp. 706-714, B.C. Decker
13. Tabibzadeh, S. (1996) The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Mol. Hum. Reprod. 2, 77-92
14. Graham, J.D. and Clarke, C.L. (1997) Physiological action of progesterone in target tissues. Endocr. Rev. 18, 502-519
15. Salamonsen, L.A. et al. (1999) Current concepts of the mechanisms of menstruation. Bailliere's Best. Pract. Res. Clin. Obstet. Gynaecol. 13, 161-179
16. Dahmoun, M. et al. (1999) Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase. J. Clin. Endocrinol. Metab. 84, 1737-1743
17. Weiderpass, E. et al. (1999) Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 353, 1824-1828
18. Sherman, M.E. (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13, 295-308
19. Cunha, G.R. et al. (1987) The endocrinology and developmental biology of the prostate. Endocr. Rev. 8, 338-362
20. Denmeade, S.R. et al. (1996) Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28, 251-265
21. Taplin, M.E. et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl. J. Med. 332, 1393-1398
22. Tilley W.D. et al. (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2, 277-285
23. Buchanan, G. et al. (2001) Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 15, 46-56
24. Thompson, E.B. et al. (1999) Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc. J. Steroid Biochem. Mol. Biol. 69, 453-461
25. Ward, I. et al. (1999) Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets. Trends Pharmacol. Sci. 20, 503-509
26. Ashwell, J.D. et al. (2000) Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 18, 309-345
27. Gould, E. and Tanapat, P. (1999) Stress and hippocampal neurogenesis. Biol. Psychiatry 46, 1472-1479
28. Reagan, L.P. and McEwen, B.S. (1997) Controversies surrounding glucocorticoid-mediated cell death in the hippocampus. J. Chem. Neuroanat. 13, 149-167
29. Sachs, L.M. et al. (1997) Apoptosis in Xenopus tadpole tail muscles involves Bax-dependent pathways. FASEB J. 11, 801-808
30. Bernal, J. and Nunez, J. (1995) Thyroid hormones and brain development. Eur. J. Endocrinol. 133, 390-398
31. Hashimoto, K. et al. (2001) An unliganded thyroid hormone receptor causes severe neurological dysfunction. Proc. Natl. Acad. Sci. U. S. A. 98, 3998-4003
32. Sporn, M.B. and Roberts, A.B. (1983) Role of retinoids in differentiation and carcinogenesis. Cancer Res. 43, 3034-3040
33. Lotan, R. et al. (1990) Inhibition of tumor cell growth by retinoids. Methods Enzymol. 190, 100-110
34. Kastner, P et al. (1995) Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83, 859-869
35. Niederreither, K. et al. (1999) Embryonic retinoic acid synthesis is essential for early mouse post-implantation development. Nat. Genet. 21, 444-448
36. Dupe, V. et al. (1999) Essential roles of retinoic acid signaling in interdigital apoptosis and control of BMP-7 expression in mouse autopods. Dev. Biol. 208, 30-43
37. Moon, R.C. et al. (1994) Retinoids and cancer in experimental animals. In The Retinoids (Sporn, M.B. et al., eds), pp. 573-595, Raven Press
38. Kelloff, G.J. et al. (1996) New agents for cancer chemoprevention. J. Cell Biochem. 26 (Suppl.), 1-28
39. Lotan, R. (1996) Retinoids in cancer chemoprevention. FASEB J. 10, 1031-1039
40. Hong, W.K. et al. (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. New Engl. J. Med. 315, 1501-1505
41. Hong, W.K. et al. (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. New Engl. J. Med. 323, 795-801
42. Veronesi, U. et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91, 1847-1856
43. Lawrence, J.A. et al. (2001) Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity pharmacokinetic, and biomarker evaluations. J. Clin. Oncol. 19, 2754-2763
44. Zujewski, J. et al. (2001) Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Cancer Res. 3, 66-75
45. Slack, J.L. and Gallagher, R.E. (1999) The molecular biology of acute promyelocytic leukemia. Cancer Treat. Res. 99, 75-124
46. Fenaux, P. et al. (2001) All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. 38, 13-25
47. Fantl, V. et al. (1995) Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9, 2364-2372
48. Sicinski, P. et al. (1995) Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82, 621-630
49. Wang,TC. et al. (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669-671
50. Weinstat-Saslow, D. et al. (1995) Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1, 1257-1260
51. Vos, C.B. et al. (1999) Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J. Pathol. 187, 279-284
52. Altucci, L. et al. (1996) 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12, 2315-2324
53. Altucci, L. et al. (1997) Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 138, 978-984
54. Sabbah, M. et al. (1999) Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U. S. A. 96, 11217-11222
55. Planas-Silva, M.D. et al. (2001) AIB1 enhances estrogen-dependent induction of cyclin d1 expression. Cancer Res. 61, 3858-3862
56. Zwijsen, R.M. et al. (1998) Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 12, 3488-3498
57. Zwijsen, R.M. et al. (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88, 405-415
58. Ankrapp, D.P. et al. (1998) Role of epidermal growth factor in the acquisition of ovarian steroid hormone responsiveness in the normal mouse mammary gland. J. Cell Physiol. 174, 251-260
59. Cunha, G.R. et al. (1997) Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J. Mammary Gland Biol. Neoplasia 2, 393-402
60. Musgrove, E.A. et al. (1998) Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18, 1812-1825
61. Musgrove, E.A. et al. (1997) Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol. Endocrinol. 11, 54-66
62. Curtis, S.W. et al. (1996) Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc. Natl. Acad. Sci. U. S. A. 93, 12626-12630
63. Cooke, P.S. et al. (1997) Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc. Natl. Acad. Sci. U. S. A. 94, 6535-6540
64. Nawaz, S. et al. (1987) Hormonal regulation of cell death in rabbit uterine epithelium. Am. J. Pathol. 127, 51-59
65. Pecci, A. et al. (1997) Progestins preventapoptosis in a rat endometrial cell line and increase the ratio of bcl-XL to bcl-XS. J. Biol. Chem. 272, 11791-11798
66. Tao,X.J. et al. (1997) Differential expression of members of the bcl-2 gene family in proliferative and secretory human endometrium: glandular epithelial cell apoptosis is associated with increased expression of bax. J. Clin. Endocrinol. Metab. 82, 2738-2746
67. Kuiper, G.G. et al. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93, 5925-5930
68. Korach, K.S. (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266, 1524-1527
69. Krege, J.H. et al. (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. U. S. A. 95, 15677-15682
70. Roger, P. et al. (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61, 2537-2541
71. Weihua, Z. et al. (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. U. S. A. 98, 6330-6335
72. Pettersson, K. et al. (1997) Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol. Endocrinol. 11, 1486-1496
73. Cowley S.M. et al. (1997) Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 272, 19858-19862
74. Lu, S. et al. (1997) Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 57, 4511-4516
75. Hofman, K. et al. (2001) E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem. Biophys. Res. Commun. 283, 97-101
76. Migliaccio, A. et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 19, 5406-5417
77. Reutens, A.T. et al. (2001) Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol. 15, 797-811
78. Park, J.J. et al. (2000) Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 60, 5946-5949
79. Suzuki, A. et al. (1996) Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 13, 31-37
80. Chen, Y. et al. (1996) Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ. 7, 1571-1578
81. Gronemeyer, H. and Laudet, V. (1995) Transcription factors 3: nuclear receptors. Protein Profile 2, 1173-1308
82. Mangelsdorf, D.J. and Evans, RM. (1995) The RXR heterodimers and orphan receptors. Cell 83, 841-850
83. Chambon, P. (1996) A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954
84. Fenaux, P. and Degos, L. (1997) Differentiation therapy for acute promyelocytic leukemia. New Engl. J. Med. 337, 1076-1077
85. Minucci, S. and Pelicci, PG. (1999) Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin. Cell Dev. Biol. 10, 215-225
86. Altucci, L. et al. (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7, 680-686
87. Benoit, G. et al. (1999) RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18, 7011-7018
88. Benoit, G. et al. (2001) Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol. Endocrinol. 15, 1154-1169
89. Sun, S.Y. et al. (1999) Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 59, 2493-2498
90. Sun, S.Y. et al. (2000) Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(l-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) throughup-regulation of TRAIL receptors in human lung cancer cells. Cancer Res. 60, 7149-7155
91. Sun, S.Y. et al. (2000) Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 19, 4513-4522
92. Welsh, J. (1994) Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell Biol. 72, 537-545
93. Zhuang, S.H. and Burnstein, K.L. (1998) Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139, 1197-1207
94. Diaz, G.D. et al. (2000) Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60, 2304-2312
95. Danielsson, C. et al. (1998) Differential apoptotic response of human melanoma cells to 1alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ. 5, 946-952
96. Liu, M. et al. (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10, 142-153
97. Hershberger, P.A. et al. (1999) 1,25-Dihydroxycholecalciferol (1,25-DS) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res. 59, 2644-2649
98. Rots, N.Y. et al. (1999) Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 93, 2721-2729
99. Verlinden, L. et al. (2000) Two novel 14-epianalogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res. 60, 2673-2679
100. VanWeelden, K. et al. (1998) Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 139, 2102-2110
101. Blutt, S.E. et al. (2000) Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141, 10-17
102. Mathiasen, I.S. et al. (1999) Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 59, 4848-4856
103. McGuire, T.F. et al. (2001) Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells: selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem. 276, 26365-26373
104. Subramaniam, N. et al. (2001) Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J. Biol. Chem. 276, 15741-15746
105. Yanagisawa, J. et al. (1999) Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283, 1317-1321
106. Liu, M. et al. (1996) Transcriptional activation of the human p21 (WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J. Biol. Chem. 271, 31723-31728
107. Gottlicher, M. et al. (1998) Transcriptional cross-talk, the second mode of steroid hormone receptor action. J. Mol. Med. 76, 480-489
108. Reichardt, H.M. et al. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93, 531-541
109. Reichardt, H.M. et al. (2000) New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv. Pharmacol. 47, 1-21
110. Thompson, E.B. (1999) Mechanisms of T-cell apoptosis induced by glucocorticoids. Trends Endocrinol. Metab. 10, 353-358
111. Ramdas, J. et al. (1999) Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res. 59, 1378-1385
112. Tonko, M. et al. (2001) Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis. FASEB J. 15, 693-699
113. Resche-Rigon, M. and Gronemeyer, H. (1998) Therapeutic potential of selective modulators of nuclear receptor action. Curr. Opin. Chem. Biol. 2, 501-507
114. Chen, J.Y. et al. (1995) RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14, 1187-1197
115. List, H.J. et al. (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator aib1 is a rate-limiting factor for estrogen-dependent growth of human mcf-7 breast cancer cells. J. Biol. Chem. 276, 23763-23768
116. Yu, Q. et al. (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021